India’s government for the first time will allow a generic-drug maker to produce and sell cheaper copies of a patented cancer medicine, a decision that pressures brand-name manufacturers to lower prices.
Natco Pharma Ltd. (NTCPH) received a so-called compulsory license to make Bayer AG (BAYN)’s Nexavar, which goes by the generic name sorafenib, and will have to sell it at a 97 percent discount to Bayer’s existing product, India’s Controller General of Patents Designs and Trademarks said yesterday in a statement on its website. Read the rest of this entry »
Iressa (gefitinib) Improves Progression-free Survival over Standard Chemotherapy in Patients with NSCLC with EGFR Mutations. Read the rest of this entry »
Lung cancer has become more common in China in recent years. The rise in tobacco consumption is the most important factor in this increase. As is the case in many developing countries, indoor air pollution from poorly ventilated stoves is an additional risk factor, particularly for women. Read the rest of this entry »
Integration of Novel Agents Into Treatment Regimens for Patients With Advanced Non-Small-Cell Lung Cancer
Treatment options in non-small-cell lung cancer (NSCLC) have expanded recently due to the demonstration of efficacy of targeted agents alone or in combination with existing cytotoxic chemotherapies. Research with these approaches is ongoing, and the 2006 American Society of Clinical Oncology meeting featured presentations from studies of epidermal growth factor (EGFR) inhibitors and antiangiogenic agents, as well as on the use of other novel compounds. Read the rest of this entry »
Most Commented